Lifecore Biomedical signs commercial site transfer deal with global pharma company
LFCR•Commercial site transfer agreement
Lifecore Biomedical signed an agreement to transfer a commercially marketed injectable drug product into its pipeline for future commercial manufacturing.
The work covers technical transfer services to support commercial production for a global pharmaceutical customer.
Revenue timing and pipeline impact
The program is expected to generate commercial revenue in 2028.
The deal adds Lifecore’s seventh late-stage commercial program, bringing the 2026 pipeline additions to 11 programs.
